| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3233/JAD-150826 |
| P698 | PubMed publication ID | 26836177 |
| P50 | author | Lan Tan | Q66911182 |
| Jin-Tai Yu | Q37837814 | ||
| P2093 | author name string | Jun Wang | |
| P2860 | cites work | A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial | Q50578805 |
| Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. | Q50620222 | ||
| Effects of a multidomain lifestyle modification on cognitive function in older adults: an eighteen-month community-based cluster randomized controlled trial | Q50628247 | ||
| A controlled trial of homocysteine lowering and cognitive performance | Q50725116 | ||
| A randomized controlled trial of dietetic interventions to prevent cognitive decline in old age hostel residents | Q50744434 | ||
| Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study | Q50746303 | ||
| Multifactorial vascular risk factor intervention to prevent cognitive impairment after stroke and TIA: a 12-month randomized controlled trial | Q50926022 | ||
| Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). | Q50951757 | ||
| A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. | Q50952335 | ||
| Complex mental and physical activity in older women and cognitive performance: a 6-month randomized controlled trial | Q51056748 | ||
| Diabetes mellitus and the risk of dementia: The Rotterdam Study. | Q53231897 | ||
| Prevention trials in Alzheimer's disease: an EU-US task force report. | Q53428918 | ||
| Alzheimer disease: Lessons from immunotherapy for Alzheimer disease. | Q53462532 | ||
| Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease | Q21131065 | ||
| Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial | Q21136174 | ||
| Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 | ||
| Effects of cognitive training interventions with older adults: a randomized controlled trial | Q24596660 | ||
| Long-term effects of cognitive training on everyday functional outcomes in older adults | Q24602305 | ||
| Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial | Q24607545 | ||
| Testing the right target and right drug at the right stage | Q26864854 | ||
| Mild cognitive impairment: clinical characterization and outcome | Q28140626 | ||
| Aspirin dose for the prevention of cardiovascular disease: a systematic review | Q28210030 | ||
| Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial | Q28286628 | ||
| Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study | Q28302829 | ||
| Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study | Q28366850 | ||
| Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer's disease | Q28486236 | ||
| The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 | ||
| Mild cognitive impairment as a diagnostic entity | Q29619568 | ||
| A cognitive training program based on principles of brain plasticity: results from the Improvement in Memory with Plasticity-based Adaptive Cognitive Training (IMPACT) study | Q30430555 | ||
| Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial | Q48187875 | ||
| Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics | Q48346421 | ||
| Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial | Q48359732 | ||
| Adaptive trials in clinical research: scientific and ethical issues to consider | Q48429604 | ||
| Ladostigil prevents age-related glial activation and spatial memory deficits in rats | Q48511565 | ||
| Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia | Q48550309 | ||
| Ginkgo biloba for prevention of dementia: a randomized controlled trial | Q30437036 | ||
| Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. | Q30561855 | ||
| Glucose levels and risk of dementia | Q30574095 | ||
| Disease-modifying therapies for Alzheimer disease: challenges to early intervention | Q31133189 | ||
| Alzheimer's disease: clinical trials and drug development | Q33349401 | ||
| The A4 study: stopping AD before symptoms begin? | Q33725775 | ||
| Diagnosis and biomarkers of predementia in Alzheimer's disease. | Q33777509 | ||
| Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial | Q34013637 | ||
| Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline | Q34113201 | ||
| The LIFE Cognition Study: design and baseline characteristics | Q34134812 | ||
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
| Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift | Q34160589 | ||
| An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease | Q34364368 | ||
| Vitamin E and donepezil for the treatment of mild cognitive impairment | Q34411313 | ||
| The preclinical Alzheimer cognitive composite: measuring amyloid-related decline | Q34422469 | ||
| Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). | Q34635541 | ||
| A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment | Q34668003 | ||
| A randomized controlled trial of cognitive training using a visual speed of processing intervention in middle aged and older adults. | Q34708302 | ||
| Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial | Q34804070 | ||
| Prediction of cognitive decline based on hemispheric cortical surface maps of FDDNP PET | Q35015645 | ||
| Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study--a randomized controlled trial | Q35120244 | ||
| Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives | Q35182733 | ||
| Advances in the prevention of Alzheimer's disease and dementia | Q35322167 | ||
| The older people, omega-3, and cognitive health (EPOCH) trial design and methodology: a randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and wellbeing in cognitively healthy ol | Q35533506 | ||
| Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy | Q35905639 | ||
| Preventing cognitive decline in older African Americans with mild cognitive impairment: design and methods of a randomized clinical trial | Q35992047 | ||
| Resistance training and executive functions: a 12-month randomized controlled trial | Q36251917 | ||
| Risk of dementia in diabetes mellitus: a systematic review | Q36345254 | ||
| Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial | Q36507890 | ||
| Prevention of Alzheimer disease | Q36569256 | ||
| Effectiveness of cognitive training for Chinese elderly in Hong Kong | Q36627213 | ||
| Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. | Q36759184 | ||
| A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial | Q36797166 | ||
| Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog) | Q37063691 | ||
| Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial | Q37180577 | ||
| Disease-modifying therapies in Alzheimer's disease | Q37218210 | ||
| Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls | Q37259426 | ||
| Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial | Q37574486 | ||
| Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. | Q37691087 | ||
| Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. | Q37711677 | ||
| National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline | Q37765090 | ||
| Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial | Q38041758 | ||
| Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease | Q38116974 | ||
| Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward | Q38184618 | ||
| Investigational drugs in Alzheimer's disease: current progress | Q38202185 | ||
| Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis | Q38215977 | ||
| Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return? | Q38224958 | ||
| The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults | Q38453707 | ||
| Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial | Q38487526 | ||
| Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective | Q38516632 | ||
| Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions | Q38554910 | ||
| Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial | Q38961347 | ||
| A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women | Q39105871 | ||
| Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease | Q40201129 | ||
| A phase 3 trial of semagacestat for treatment of Alzheimer's disease | Q42710153 | ||
| Vitamins B(12), B(6), and folic acid for cognition in older men. | Q42879215 | ||
| Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study | Q42925710 | ||
| Chronic endurance exercise training prevents aging-related cognitive decline in healthy older adults: a randomized controlled trial | Q43208343 | ||
| Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study | Q43570023 | ||
| Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress | Q43689443 | ||
| 2010 Alzheimer's disease facts and figures | Q44014954 | ||
| Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial | Q44122322 | ||
| Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease | Q44191043 | ||
| Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease | Q44438340 | ||
| Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial | Q44456433 | ||
| Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force | Q44595079 | ||
| Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial | Q45028143 | ||
| A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment | Q45292749 | ||
| Exergaming and older adult cognition: a cluster randomized clinical trial. | Q45339533 | ||
| Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease | Q45789942 | ||
| The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress | Q46171398 | ||
| Safety and efficacy of galantamine in subjects with mild cognitive impairment | Q46717012 | ||
| A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study | Q46720790 | ||
| Association of Alzheimer's disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study | Q48006785 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 927-945 | |
| P577 | publication date | 2016-01-19 | |
| P1433 | published in | Journal of Alzheimer's Disease | Q6294755 |
| P1476 | title | Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives | |
| P478 | volume | 50 |
| Q92543622 | Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials |
| Q52675910 | Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. |
| Q92463647 | Clinician-patient communication during the diagnostic workup: The ABIDE project |
| Q38966308 | Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients. |
| Q92881845 | Neuroinflammation and Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches |
| Q52595131 | Oxidant/Antioxidant Imbalance in Alzheimer's Disease: Therapeutic and Diagnostic Prospects. |
| Q91970568 | Recruitment, Retainment, and Biomarkers of Response; A Pilot Trial of Lithium in Humans With Mild Cognitive Impairment |
| Q60301953 | The Age-Well randomized controlled trial of the Medit-Ageing European project: Effect of meditation or foreign language training on brain and mental health in older adults |
| Q47567135 | The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset |
Search more.